Top

Published in:

01-09-2009 | Brief Report

Patients treated by tegaserod for irritable bowel syndrome with constipation showed significant improvement in fibromyalgia symptoms. A pilot study

Authors: Tatiana Reitblat, Doron Zamir, Ilia Polishchuck, Galina Novochatko, Stephen Malnick, Leonid Kalichman

Published in: Clinical Rheumatology | Issue 9/2009

Abstract

The symptoms of irritable bowel syndrome (IBS) are commonly seen in fibromyalgia (FM) patients. This study aimed to evaluate the effect of 5-hydroxytryptamin-4 receptor partial agonist (tegaserod) on the symptoms of FM among the patients who receive the medicine because of IBS. Forty-one female patients with IBS and constipation, which were subjects to tegaserod treatment, were examined by rheumatologist and 14 were found to suffer from FM. The fibromyalgia impact questionnaire (FIQ) and clinical examination were done before tegaserod treatment and 1 month after. The IBS status, the total FIQ score, the number of tender points and pain in tender points were lowered significantly after the treatment (p < 0.001 for all variables). The results of this pilot study provide the preliminary evidence that FM patients can benefit from treatment by 5-hydroxytryptamin-4 receptor partial agonist. Additional studies are needed to support this conclusion.

Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P et al (1990) The American College of Rheumatology 1990 criteria for the classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33:160–172PubMedCrossRef

Yunus MB, Masi AT, Calabro JJ, Miller KA, Feigenbaum SL (1981) Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Semin Arthritis Rheum 11:151–171PubMedCrossRef

Goldenberg DL (1987) Fibromyalgia syndrome: an emerging but controversial condition. JAMA 257:2782–2787PubMedCrossRef

Hudson JI, Goldenberg DL, Pope HG Jr, Keck PE Jr, Schlesinger L (1992) Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med 92:363–367PubMedCrossRef

Clouw DJ, Chrousos GP (1997) Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenetic mechanism. Neuroimmunomodulation 4:134–153

Sperber AD, Atzmon Y, Neumann L, Weisberg I, Shalit Y, Abu-Shakrah M, Fich A, Buskila D (1999) Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Am J Gastroenterology 94:3541–3546CrossRef

Veale D, Kavanagh G, Fielding JF, Fitzgerald O (1991) Primary fibromyalgia and the irritable bowel syndrome. Br J Rheumatol 30:220–222PubMedCrossRef

Aaron LA, Buchwald D (2001) Fibromyalgia and other unexplained clinical conditions. Cur Rheum Rep 3:116–122CrossRef

Everhart JE, Renault PF (1991) Irritable bowel syndrome in office based practice in the United States. Gastroenterology 100:998–1005PubMed

10.

Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ 3rd (1991) Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 101:927–934PubMed

11.

Brandt LJ, Bjorkman D, Fennerty MB, Locke GR, Olden K, Peterson W, Quigley E, Schoenfeld P, Schuster M, Talley N (2002) Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 97:S7–S26PubMed

12.

Levy RL, Jones KR, Whitehead WE, Feld SI, Talley NJ, Corey LA (2001) Irritable bowel syndrome in twins: hereditary and social learning both contribute to etiology. Gastroenterology 121:799–804PubMedCrossRef

13.

Moldofsky H, Warsh JJ (1978) Plasma tryptophan and musculoskeletal pain in non-articular rheumatism (“fibrositis syndrome”). Pain 5:65–71PubMedCrossRef

14.

Moldofsky H (1982) Rheumatic pain modulation syndrome: the interrelationships between sleep, central nervous system serotonin, and pain. Adv Neurol 33:51–57PubMed

15.

Russell IJ, Michalek JE, Vipraio GA, Fletcher EM, Wall K (1989) Serum amino acids in fibrositis/fibromyalgia syndrome. J Rheumatol Suppl 19:158–163PubMed

16.

Prior A, Read NW (1993) Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5-HT3-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 7:175–180PubMedCrossRef

17.

Fried M, Beglinger C, Bobalj NG, Minor N, Coello N, Michetti P, TegaSwiss Study Group (2005) Tegaserod is safe, well tolerated and effective in the treatment of patients with non-diarrhoea irritable bowel disease syndrome. Eur J Gastroenerol Hepatol 17:421–427CrossRef

18.

Evans BW, Clark WK, Moore DJ, Whorwell PJ (2007) Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev 4:CD003960PubMed

19.

Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA (1999) Functional bowel disorders and functional abdominal pain. Gut 45(Suppl 2):II43–II47PubMed

20.

Buskila D, Neumann L (1996) Assessing functional disability and health status of women with fibromyalgia: validation of a Hebrew version of the fibromyalgia impact questionnaire. J Rheumatol 23:903–906PubMed

21.

Hrycaj P, Stratz T, Mennet P, Müller W (1996) Pathogenetic aspects of responsiveness to ondansetron (5HT type 3 receptor antagonist) in patients with primary fibromyalgia syndrome—a preliminary study. J Rheumatol 23:1418–1423PubMed

22.

Spath M, Stratz T, Neeck G, Kötter I, Hammel B, Amberger CC, Haus U, Färber L, Pongratz D, Müller W (2004) Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia. Scan J Rheumatol 33:267–270CrossRef

23.

Weinstock LB, Fern SE, Duntley SP (2008) Restless legs syndrome in patients with irritable bowel syndrome: response to small intestinal bacterial overgrowth therapy. Dig Dis Sci 53:1252–1256PubMedCrossRef

24.

Yunus MB, Aldag JC (1996) Restless legs syndrome and leg cramps in fibromyalgia syndrome: a controlled study. BMJ 312:1339PubMed

Title: Patients treated by tegaserod for irritable bowel syndrome with constipation showed significant improvement in fibromyalgia symptoms. A pilot study
Authors: Tatiana Reitblat
Doron Zamir
Ilia Polishchuck
Galina Novochatko
Stephen Malnick
Leonid Kalichman
Publication date: 01-09-2009
Publisher: Springer-Verlag
Published in: Clinical Rheumatology / Issue 9/2009
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-009-1194-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Patients treated by tegaserod for irritable bowel syndrome with constipation showed significant improvement in fibromyalgia symptoms. A pilot study

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2009

Higher comorbidity, poor functional status and higher health care utilization in veterans with prevalent total knee arthroplasty or total hip arthroplasty

Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis

Patients’ experiences of a diagnosis of Hughes’ syndrome

Fatigue in patients with ankylosing spondylitis: relationships with disease-specific variables, depression, and sleep disturbance

Macroscopic features of knee synovitis in early untreated Behçet disease and psoriatic arthritis

Rheumatoid leptomeningitis: rare complication of rheumatoid arthritis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page